Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs TE Connectivity plc Ordinary Shares (TEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs TE Connectivity plc Ordinary Shares — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B), while TE Connectivity plc Ordinary Shares trades at $210.29 (market cap $62.51B). The key difference: TE Connectivity plc Ordinary Shares is far larger — about 8.3× Spyre Therapeutics Inc. Common Stock's market cap, and TE Connectivity plc Ordinary Shares pays a 1.44% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and TE Connectivity plc Ordinary Shares for 0 Days on average.
| SYRE | TEL | |
|---|---|---|
Market Cap | $7.52B | $62.51B |
Volume | 1,441,031 | 2,249,319 |
Sector | Health | Technology |
52-Week High | $108.92 | $249.00 |
52-Week Low | $22.18 | $195.84 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.52B | $66.90B |
Dividend Yield | — | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
TE Connectivity (TEL) trades at $215.92, down 0.63% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 15.61% net margin, and improving cash flow. Recent analyst upgrades highlight growth potential as the company prepares for Q4 2026 earnings on October 28.
TEL offers solid investment appeal with 23.54% ROE and 48% analyst buy ratings, though near-term volatility may persist. The $253.22 consensus target implies 17% upside, supported by operational strength and dividend stability. Key risks include market sensitivity and execution challenges in competitive electronics components sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About TE Connectivity plc Ordinary Shares
TE Connectivity designs and manufactures connectivity and sensor solutions. Its products support transportation, energy networks, industrial automation, communications infrastructure, and medical technology.
Read more on TEL →
